Organon, Shanghai Henlius Biotech Launch Denosumab Biosimilars in Canada

MT Newswires Live

06/23

Organon's (OGN) Canada unit and Shanghai Henlius Biotech launched Bildyos and Tuzemty injections in Canada, the companies said Tuesday.

The products, denosumab biosimilars to Prolia and Xgeva, are approved for all indications of the reference medicines and are used to treat osteoporosis and bone conditions linked to cancer, according to the companies.

The launches expand Organon's biosimilar portfolio in Canada and follow a 2022 licensing and supply agreement with Henlius that granted Organon exclusive commercialization rights for the products outside China, the companies said.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2645838996"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645838996\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645838996?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 18:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645838996","market":"nz","top_or_hot":-1,"title":"Organon, Shanghai Henlius Biotech Launch Denosumab Biosimilars in Canada","media":"MT Newswires Live","content":"<html><body><p> Organon's (OGN) Canada unit and <a href=\"https://laohu8.com/S/SGBCF\">Shanghai Henlius Biotech</a> launched Bildyos and Tuzemty injections in Canada, the companies said Tuesday.</p><p>The products, denosumab biosimilars to Prolia and Xgeva, are approved for all indications of the reference medicines and are used to treat osteoporosis and bone conditions linked to cancer, according to the companies.</p><p>The launches expand Organon's biosimilar portfolio in Canada and follow a 2022 licensing and supply agreement with Henlius that granted Organon exclusive commercialization rights for the products outside China, the companies said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Organon, Shanghai Henlius Biotech Launch Denosumab Biosimilars in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrganon, Shanghai Henlius Biotech Launch Denosumab Biosimilars in Canada\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-23 18:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Organon's (OGN) Canada unit and <a href=\"https://laohu8.com/S/SGBCF\">Shanghai Henlius Biotech</a> launched Bildyos and Tuzemty injections in Canada, the companies said Tuesday.</p><p>The products, denosumab biosimilars to Prolia and Xgeva, are approved for all indications of the reference medicines and are used to treat osteoporosis and bone conditions linked to cancer, according to the companies.</p><p>The launches expand Organon's biosimilar portfolio in Canada and follow a 2022 licensing and supply agreement with Henlius that granted Organon exclusive commercialization rights for the products outside China, the companies said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645838996","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645838996","pubTimestamp":1782212271,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Organon's  Canada unit and Shanghai Henlius Biotech launched Bildyos and Tuzemty injections in Canada, the companies said Tuesday.The products, denosumab biosimilars to Prolia and Xgeva, are approved for all indications of the reference medicines and are used to treat osteoporosis and bone conditions linked to cancer, according to the companies.The launches expand Organon's biosimilar portfolio in Canada and follow a 2022 licensing and supply agreement with Henlius that granted Organon exclusive commercialization rights for the products outside China, the companies said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4559":"巴菲特持仓","BK4007":"制药","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","XBI":"SPDR S&P Biotech ETF","BK4588":"碎股","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","OGN":"Organon & Co","BK4585":"ETF&股票定投概念","BK4581":"高盛持仓","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC"},"translate_title":"Organon、上海复宏汉霖生物在加拿大推出Denosumab生物仿制药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OGN":1,"XBI":1.5},"content_text":"Organon's (OGN) Canada unit and Shanghai Henlius Biotech launched Bildyos and Tuzemty injections in Canada, the companies said Tuesday.The products, denosumab biosimilars to Prolia and Xgeva, are approved for all indications of the reference medicines and are used to treat osteoporosis and bone conditions linked to cancer, according to the companies.The launches expand Organon's biosimilar portfolio in Canada and follow a 2022 licensing and supply agreement with Henlius that granted Organon exclusive commercialization rights for the products outside China, the companies said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}